Skip to main content
Fig. 7 | BMC Cancer

Fig. 7

From: Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials

Fig. 7

Forest plots of the pooled RRs for grade 3 or higher hematological (including neutropenia, anemia, thrombocytopenia, and lymphopenia) and non-hematological adverse events (including pneumonia, diarrhea, and fatigue) of the patients with MM in the MAbs targeting SLAMF7 group versus control group. The RR < 1 favours the MAb group. The size of the blocks or diamonds represents the weight of the fixed effects model in the meta-analysis

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us